We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bioxcel Therapeutics
7 own
6 watching
Current Price
$0
$0.11
(0.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
799.22M
52-Week High
32.96
52-Week Low
8.795
Average Volume
0.26M
Dividend Yield
--
P/E Ratio
--
Market Capitalization799.22M52-Week High32.9652-Week Low8.795Average Volume0.26MDividend Yield--P/E Ratio--What does the Bioxcel Therapeutics do?
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
How much money does Bioxcel Therapeutics make?
News & Events about Bioxcel Therapeutics.
Ticker Report
6days ago
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) insider Frank Yocca sold 50,000 shares of the businesss stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now ...
Zolmax
6days ago
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) insider Frank Yocca sold 50,000 shares of the businesss stock in a transaction on Friday, January 20th. The stock was sold at an average price of $30.00, for a total value of $1,500,000.00. Following the transaction, the insider now directly owns 8...
Globe Newswire
1month ago
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel ...
Ticker Report
1month ago
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) CEO Vimal Mehta sold 30,000 shares of the companys stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the sale, the chief...
Zolmax
1month ago
BioXcel Therapeutics, Inc. (NASDAQ:BTAI Get Rating) CEO Vimal Mehta sold 30,000 shares of the companys stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the sale, the chief executive ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioxcel Therapeutics share price today?
Can Indians buy Bioxcel Therapeutics shares?
How can I buy Bioxcel Therapeutics shares from India?
Can Fractional shares of Bioxcel Therapeutics be purchased?
What are the documents required to start investing in Bioxcel Therapeutics stocks?
What is today’s traded volume of Bioxcel Therapeutics?
What is today’s market capitalisation of Bioxcel Therapeutics?
What is the 52-Week High and Low Range of Bioxcel Therapeutics?
What percentage is Bioxcel Therapeutics down from its 52-Week High?
What percentage is Bioxcel Therapeutics up from its 52-Week Low?
Current Price
$0
$0.11
(0.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.